Drug Profile
WX 554
Alternative Names: WX-554Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator UCB
- Developer WILEX AG
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 14 Apr 2014 Discontinued - Phase-I for Cancer in Germany (IV)
- 14 Apr 2014 Discontinued - Phase-I for Cancer in Germany (PO)
- 14 Apr 2014 Discontinued - Phase-I for Solid tumours (combination therapy) in United Kingdom (PO)